-
QIAGEN provides clinical decision support through its QIAGEN Clinical Insights Interpret One software for expanded Marsden360 liquid biopsy service now offering ESR1 circulating tumor DNA testing for breast cancer patients
-
Marsden360 offers a minimally invasive alternative to tissue biopsies, enabling rapid identification of mutations in patients with solid tumors
-
QIAGEN Clinical Insight Interpret One enables reliable variant interpretation by combining AI and human curation, ultimately leading to actionable insights improving patient outcomes
Redwood City, California -- QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN and the leading provider of bioinformatics software and biomedical knowledge content, today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) Interpret One, is supporting The Royal Marsden National Health Service (NHS) Foundation Trust’s new offering for ESR1 genomic testing, a mutation associated with breast cancer, as part of its workflow for Marsden360, an innovative liquid biopsy service.
On January 20, 2025, the NHS expanded its National Genomic Test Directory to include ESR1 circulating tumor DNA (ctDNA) testing for breast cancer patients. This milestone enables oncologists to detect ESR1 mutations through a simple blood test, guiding personalized treatment strategies for patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer.
Since its launch in 2021, Marsden360 is available for private and clinical trial patients at the Royal Marsden Hospital, a specialist oncology hospital in London, United Kingdom. The service has completed thousands of ctDNA tests as part of an NHS England national study and is advancing toward inclusion in the insurance-covered test directory.
Marsden360 is a blood-based test that analyzes 74 genes to detect genetic mutations in ctDNA, providing a minimally invasive alternative to traditional biopsies. The service enables oncologists to rapidly identify genetic changes in patients with solid tumors, guiding personalized treatment strategies — especially for cases where tissue biopsies are not feasible.
By integrating QCI Interpret One, clinicians gain unmatched accuracy, speed, and consistency in variant interpretation, allowing them to deliver high-confidence, actionable insights for precision oncology treatments.
”The selection of QCI Interpret One by Royal Marsden is yet another demonstration of QIAGEN’s leadership in clinical interpretation,” said Dominic John, Vice President, QIAGEN Digital Insights. “QCI Interpret One supports Royal Marsden’s Marsden360 service by combining QIAGEN’s expert-curated database with advanced AI-powered curation. The flexibility of our solution, combined with the quality of our knowledge is why the top and largest clinical testing labs in the world trust and rely on QCI Interpret One for their interpretation and reporting needs.”
“The adoption of QCI Interpret One as part of our Marsden360 workflow has significantly advanced our ability to efficiently classify somatic variants in solid tumors, confidently match therapies to biomarkers, and identify clinical trials located near a patient’s home. Now as we expand our Marsden360 offering to include testing for ESR1 variants in breast cancer, we are excited to bring this valuable service to new patients with more precise and informed treatment decisions guided by QCI Interpret.” said Michael Valgañón, PhD, Head of Clinical Genomics at the Royal Marsden NHS Foundation Trust.
QCI Interpret One is a clinical decision support software that combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered curation) to enable high-confidence variant interpretation and reporting.
The software dynamically computes pathogenicity and actionability based on professional guidelines for every variant in over 31,000 cancer types with full transparency. To simplify and accelerate interpretation, users have access to over 600,000 preformulated, oncologist-reviewed variant impact summaries to build custom, patient-specific reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and clinical trials.
Looking ahead, Royal Marsden and QIAGEN are exploring additional collaborations within the NHS, including anticipated projects on rapid testing for lung cancer and acute myeloid leukemia (AML) using QCI Secondary and QCI Interpret One to streamline clinical NGS workflows. This expanded partnership underscores QIAGEN’s commitment to transforming cancer care by providing high-confidence insights to support clinicians in delivering tailored patient treatments.
For more information about QCI Interpret One, visit: https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/qiagen-clinical-insight/qci-interpret-one/.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit
www.qiagen.com.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the “Risk Factors” contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.